Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative)						3 Months Ended		9 Months Ended
Commitments and Contingencies (Details Narrative)	May 13, 2022 USD ($)	Feb. 08, 2022 USD ($)	Nov. 19, 2021 USD ($) ft²	Mar. 26, 2021 USD ($)	Oct. 05, 2020	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Loss Contingencies [Line Items]
Monetary damages estimated amount	$ 370,000
Project fee								$ 2,100,000
Project fee incurred								924,000
Research and development expense						$ 2,743,000	$ 1,008,000	5,969,000	$ 3,287,000
Remaining commitments						601,000		601,000
Other Commitments, Description					On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. The Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13 million, of which $10.5 million was incurred and recorded in prior years.
Patent expense						90,000	67,000	313,000	339,000
Rent expense		$ 415	$ 9,450			29,000		87,000
Scientific Research Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense						192,000	541,000	575,000	541,000
Master Services Agreement [Member]
Loss Contingencies [Line Items]
Research and development arrangement								13,000,000
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross								10,500,000
Master Service Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense						720,000	$ 528,000	1,900,000	$ 677,000
2016 Patent Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Proceeds from upfront amount						200,000		200,000
Maintenance fee								100,000
Performance milestone payments								3,100,000
Sales milestone payments								1,000,000.0
Gross sales								250,000,000
Sales revenue								5,000,000.0
Cumulative gross sales								$ 500,000,000
2016 Patent Exclusive License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage								4.00%
Annual royalty payments								$ 250,000
2016 Patent Exclusive License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage								6.00%
Annual royalty payments								$ 5,000,000.0
2021 Patent License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense						$ 0		$ 0
Maintenance fee				$ 2,000,000.0
Annual royalty payments				250,000
Performance milestone payments				3,100,000
Sales milestone payments				1,000,000.0
Gross sales				250,000,000
Sales revenue				5,000,000.0
Cumulative gross sales				500,000,000
Upfront license fee				20,000
License maintenance fee, receivable				$ 5,000
2021 Patent License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Net sales percentage				2.50%
2021 Patent License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Net sales percentage				5.00%
Lease Agreements [Member]
Loss Contingencies [Line Items]
Area of land \| ft²			4,500
Commencement date			commencement date of January 1, 2022 and maturing on June 30, 2024